A Delaware federal jury has ruled that AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, owes Pfizer, an American multinational pharmaceutical corporation, $107.5 million in damages. 

________________________________________________________________________

• Pfizer wins $107.5 million in patent infringement case against AstraZeneca.

• The jury found AstraZeneca’s lung cancer drug Tagrisso violated Pfizer’s Wyeth unit patents.

• AstraZeneca will vigorously defend its rights; a separate bench trial in June could negate the verdict.

________________________________________________________________________

Pfizer Wins $107.5 Million Patent Infringement Lawsuit Against AstraZeneca Over Lung Cancer Drug Tagrisso.

The verdict comes after the jury found that AstraZeneca’s highly successful lung cancer drug, Tagrisso, infringed upon two patents held by Pfizer’s Wyeth unit.

The patents in question cover methods for treating cancer using the breast cancer drug Nerlynx, which Puma Biotechnology markets under a licensing agreement with Pfizer. 

The jury determined that AstraZeneca’s Tagrisso utilized kinase inhibitors to treat cancer in a manner similar to Nerlynx, thereby violating Pfizer’s intellectual property rights.

AstraZeneca has expressed disappointment with the verdict but remains confident in its intellectual property position regarding Tagrisso. 

The company has stated that it will vigorously defend its rights in this matter. 

Tagrisso has been a major revenue generator for AstraZeneca, earning the company nearly $5.8 billion in 2022 alone.

Pfizer, which acquired Wyeth in 2009, initiated the lawsuit against AstraZeneca in 2021. 

The case has garnered significant attention within the pharmaceutical industry, highlighting the importance of patent protection and the potential financial consequences of infringement.

While the jury has reached a verdict, the legal battle is not yet over. 

U.S. District Judge Matthew Kennelly is set to hold a separate bench trial in June to address some of AstraZeneca’s remaining defenses. 

The outcome of this trial could potentially negate the jury’s verdict.

The case highlights the complex nature of intellectual property disputes in the pharmaceutical industry, where research and development costs are high, and patent protection is crucial for companies to recoup their investments. 

The outcome of this lawsuit may have far-reaching implications for Pfizer, AstraZeneca, and the broader pharmaceutical market.

As the legal proceedings continue, industry experts and observers will closely monitor the developments in this high-stakes patent infringement case.

Subscribe to our newsletter now and get the inside edge to the financial world!